MedTrace Logo

Cervical Cancer Screening With Human Papillomavirus Testing

NCT01881659 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50000

Last updated 2023-03-14

No results posted yet for this study

Summary

HPV testing for primary cervical cancer screening of women over 30 years of age is likely to become the standard of care in the near future in many areas of the world. Its high sensitivity can significantly improve the effectiveness of screening programs and its prolonged negative predictive value can allow extension of screening intervals. However, a single HPV test has low positive predictive value and can lead to unnecessary workup and over-treatment and generate unnecessary distress. This multi-centric study will screen 50,000 women with HPV testing and compare several triage approaches that can follow HPV testing in order to make an HPV-based screening programme efficient, affordable and sustainable.

Conditions

Interventions

OTHER

HPV screening

Women who signed informed consent will be screened with HPV testing.

Sponsors & Collaborators

  • International Agency for Research on Cancer

    lead OTHER

Principal Investigators

  • Rolando Herrero, MD, PhD · International Agency for Research on Cancer (IARC)

Eligibility

Min Age
30 Years
Max Age
64 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2022-08-30
Completion
2023-12-31

Countries

  • Argentina
  • Bolivia
  • Colombia
  • Costa Rica
  • Honduras
  • Mexico
  • Paraguay
  • Peru
  • Uruguay

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01881659 on ClinicalTrials.gov